Caribou Biosciences, Inc. (CRBU) 

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

Show less

Over the last 12 months, insiders at Caribou Biosciences, Inc. have bought $0 and sold $0 worth of Caribou Biosciences, Inc. stock.

On average, over the past 5 years, insiders at Caribou Biosciences, Inc. have bought $299,343 and sold $628,685 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 7,387 shares for transaction amount of $29,553 was made by Fischesser Ryan (VP of Finance and Controller) on 2022‑01‑11.